Based on the structure of ALTB-168. ALTB-268, a second generation of the therapeutic antibody with multivalent design that leads to improve potency, is being under development. In vitro and in vivo studies with ALTB-268 have demonstrated a potentially 10-fold increase in activity of abolishing activated T cells (immune cells that cause inflammation).
The company is dedicated to bringing forth ALTB-268, currently in Phase 1 trial with heathy volunteers, into multiple autoimmune indications. Ulcerative colitis will be the first indication to be explored based on solid proof of clinical efficacy achieved with ALTB-168.
Solid Organ Transplantation
Solid organ transplantation is a potentially life-saving option for patients faced with terminal organ failure. However, immunosuppressive drugs are needed for prevention of rejection of transplanted organs and long-term administration of immunosuppressive medications has potential unfavorable consequences including increased susceptibility to opportunistic infections and malignancies.
Because of the unique MOA of ALTB-168, we believe it has the potential for a durable response allowing patients to avoid long-term administration of immunosuppressive medications. We are currently studying the use of ALTB-168 in preclinical non-human primate renal transplantation models.